Product image of Naraya Plus (Drospirenone, Ethinylestradiol | Lactose) supplied by GNH India

Naraya Plus

Active Ingredient:
Drospirenone, Ethinylestradiol | Lactose
Origin:
EU

Naraya Plus (Drospirenone, Ethinylestradiol | Lactose)

Drospirenone, the active ingredient in Naraya Plus, is a combined oral contraceptive presented as an oral tablet for oral use. It works to prevent pregnancy by suppressing ovulation, thickening cervical mucus, and inducing endometrial changes in women of reproductive age.

GNH India supplies Naraya Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. Clients benefit from reliable sourcing, transparent pricing, and dedicated technical support throughout the procurement process.

Manufacturer / TM Owner

Exeltis Poland Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Naraya Plus, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy.

  • Contraception (prevention of pregnancy): provides reliable hormonal birth control for women of reproductive age.
  • Menstrual cycle regulation: helps achieve more predictable menstrual periods and reduces cycle‑related symptoms.
  • Acne improvement: may reduce androgen‑related acne lesions in some users.

How It Works

  • Naraya Plus combines drospirenone, a synthetic progestogen with anti‑mineralocorticoid and anti‑androgenic activity, and ethinylestradiol, a synthetic estrogen. The estrogen component suppresses the mid‑cycle surge of luteinizing hormone, while drospirenone inhibits follicle‑stimulating hormone release and stabilizes the endometrium. Together they prevent ovulation, thicken cervical mucus, and alter the uterine lining, creating conditions unfavorable for fertilisation and implantation.

Side Effects

Like all hormonal contraceptives, Naraya Plus may be associated with adverse reactions.

Common Side Effects

  • Nausea: mild stomach upset often occurring early in treatment.
  • Headache: tension‑type or migraine‑like headaches.
  • Breast tenderness: temporary swelling or discomfort.
  • Spotting or breakthrough bleeding: irregular light bleeding between periods.

Serious or Rare Side Effects

  • Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
  • Hypertension: significant increase in blood pressure.
  • Liver dysfunction: abnormal liver enzyme levels or jaundice.

Precautions & Warnings

Before prescribing Naraya Plus, clinicians should consider several safety and handling precautions.

  • Contraindications: avoid use in women with history of thromboembolic disorders, estrogen‑dependent tumors, or active liver disease.
  • Smoking: do not prescribe to women over 35 who smoke heavily due to increased cardiovascular risk.
  • Medication review: assess concurrent use of drugs that affect coagulation or hepatic metabolism.
  • Monitoring: advise regular blood pressure checks and evaluation for signs of thrombosis.
  • Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Avoid Interactions

Naraya Plus can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

  • Combined hormonal contraceptives with other estrogen‑containing products: may increase risk of thrombotic events.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): can markedly reduce contraceptive efficacy.

Moderate Interactions (Monitor Closely)

  • Antifungal agents (e.g., ketoconazole): may increase plasma levels of drospirenone.
  • Antidepressants (e.g., sertraline): may affect bleeding patterns.
  • Herbal supplements containing St John’s wort: may decrease hormonal levels and reduce contraceptive reliability.

Frequently Asked Questions

Naraya Plus is a combined oral contraceptive indicated for the prevention of pregnancy in women of reproductive age. It provides hormonal regulation that suppresses ovulation, thickens cervical mucus, and alters the endometrium to reduce the chance of fertilisation and implantation.

Drospirenone is a synthetic progestogen with anti‑mineralocorticoid and anti‑androgenic properties, while ethinylestradiol is a synthetic estrogen. Together they inhibit the hypothalamic‑pituitary‑ovarian axis, preventing the luteinizing hormone surge needed for ovulation, and they modify cervical mucus and the uterine lining to create an environment unsuitable for sperm and implantation.

The dosing regimen for Naraya Plus is determined by the prescribing healthcare professional. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions must be provided by the prescriber.

Naraya Plus is contraindicated during pregnancy because it is designed to prevent conception. It is also not recommended for use while breastfeeding unless the benefits outweigh the risks, as hormonal contraceptives can affect milk production and infant exposure.

To order Naraya Plus, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naraya Plus contains drospirenone, which offers anti‑mineralocorticoid and anti‑androgenic effects that may reduce water retention and acne compared with some other progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, while the side‑effect profile may differ slightly based on the progestin component.

Store Naraya Plus at ambient temperature, preferably below 25 °C, in its original blister pack. Protect the tablets from moisture, direct sunlight and excessive heat. Do not use the product after the expiry date printed on the packaging.

Naraya Plus is taken orally as a tablet. The usual instruction is to swallow one tablet with water each day, preferably at the same time, without crushing or chewing, to maintain consistent hormone levels.

Serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis leading to stroke or myocardial infarction, severe hypertension, and liver dysfunction. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should be evaluated carefully before use.

Naraya Plus should not be used by women who are pregnant, have a known or suspected thromboembolic disorder, have estrogen‑dependent tumors, have uncontrolled hypertension, have active liver disease, or who are smokers over the age of 35. It is also contraindicated in individuals with known hypersensitivity to drospirenone, ethinylestradiol or any excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Drospirenone, Ethinylestradiol | Lactose

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT